

31 October 2025

ASX RELEASE

AMPLIA THERAPEUTICS COMMENCES TRADING ON U.S. OTCQB VENTURE MARKET

HIGHLIGHTS

- *Amplia Therapeutics has completed an uplist to the OTCQB Venture Market under the code INNMF effective 29 October 2025*
- *The uplisting to the OTCQB allows U.S. investors to trade in Amplia common stock in U.S. dollars during U.S. market hours*

Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) announces that it has begun trading on the U.S. OTCQB Venture Market under the code INNMF effective 29 October. The company has previously traded on the OTC Pink Sheets and with approval to uplist to the OTCQB, providing expanded access for U.S. investors to trade in the Company’s stock.

Amplia’s Managing Director and CEO Dr. Chris Burns stated, “The uplist to the OTCQB market enhances the Company’s ability to productively engage with U.S. investors at a time when there is increasing interest in the FAK inhibitor space and in the development of drugs for pancreatic cancer. We believe that this will provide additional opportunities to communicate with investors about the Company’s progress, including clinical milestones and corporate and financial highlights. We look forward to providing continued updates for all of our shareholders as they develop.”

The OTCQB Venture Market is a U.S. trading platform operated by OTC Markets Group that serves early-stage and developing companies. U.S.-based investors can trade in Amplia Therapeutics’ common stock in U.S. dollars during U.S. market hours, while the Company maintains its primary listing on the ASX via codes ATX and ATXOA.

The listing on the OTCQB expands the Company’s presence in the U.S. at an important stage in the Company’s development. The Company’s AMPLCITY clinical trial in advanced pancreatic cancer -- already enrolling patients in Australia -- is shortly to open at five clinical trial sites in the United States. In addition, the Company has been actively educating investors on Amplia’s FAK inhibitor program as part of an expanded capital markets campaign.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

ABN 16 165 160 841

+61 (0) 3 9123 1140 | info@ampliatx.com

Level 5, 90 William Street, Melbourne VIC 3000 Australia

www.ampliatx.com

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

U.S. Contact:

Robert Giordano
+1 (917) 327 3938
rjgiordano@ggrouplifesciences.com

Media Contact:

Haley Chartres
+61 (0) 423 139 163
haley@hck.digital

U.S. Media:

media@ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [X](#) (@ampliatx) and [LinkedIn](#).

About Narmafotinib

Narmafotinib (AMP945) is the company's best-in-class inhibitor of the validated drug target FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the [ACCENT](#) trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane® in first-line patients with advanced pancreatic cancer. The trial has already achieved its desired outcome in achieving a response rate of 33%, superior to chemotherapy alone and an interim PFS of 7.6 months has been reported. A second trial – [AMPLICITY](#) – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.